Arizona is currently home to 1666 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
NCT06848075
Recruiting
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/22/2025
Locations: Wake Research/ Tucson Neuroscience Research, Tucson, Arizona
Conditions: Acute Migraine
Register for Updates
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
NCT06742281
Recruiting
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 10016 healthy participants.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/22/2025
Locations: Velocity Clinical Research, Phoenix, Phoenix, Arizona
Conditions: COVID-19
Register for Updates
Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301
Recruiting
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona
Conditions: Advanced Melanoma
Register for Updates
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
NCT06664801
Recruiting
Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. The goal of the study is to learn: * What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this tria... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Pulmonary Associates, PA ( Site 1903), Phoenix, Arizona
Conditions: Pulmonary Arterial Hypertension
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT06496178
Recruiting
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Site 102, Prescott, Arizona
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
ADVENT Post Approval Study
NCT06431815
Recruiting
The ADVENT Post Approval Study (PAS) is a prospective, global, multicenter, observational study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Scottsdale Healthcare - Shea, Scottsdale, Arizona
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT06400472
Recruiting
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Honor Health Research Institute, Scottsdale, Arizona
Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Register for Updates
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder
NCT06384157
Recruiting
The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non opioid treatment.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2025
Locations: Elite Clinical Studies, LLC, Phoenix, Arizona
Conditions: Opioid Use Disorder
Register for Updates
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
Recruiting
In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
04/22/2025
Locations: University of Arizona, Tucson, Arizona
Conditions: Amblyopia
Register for Updates
Observational Study Protocol: LIVER-R
NCT06252753
Recruiting
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data colle... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/22/2025
Locations: Research Site, Phoenix, Arizona
Conditions: Hepatobiliary Cancers
Register for Updates
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301
Recruiting
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Western Regional Medical Center, LLC, Goodyear, Arizona
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574
Recruiting
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Mohtaseb Cancer Center and Blood Disorders, LLC, Bullhead City, Arizona
Conditions: Lung Cancer, Non-squamous, Non-small Cell
Register for Updates